Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 15/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | BRD2 | P25440 | 3/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20061675 | 0.86 | ERN1 (0.48) | BRD4CREBBPERN1BRD2 | |
| SCHEMBL18181282 | 0.84 | ERN1 (0.42) | BRD4CREBBPERN1GLABRD2 | |
| SCHEMBL18172285 | 0.84 | BRD4 (0.49) | BRD4CREBBPBRD2AAK1GABRA5 | |
| SCHEMBL18174242 | 0.83 | BRD4 (0.51) | BRD4CREBBPERN1BRD2AAK1 | |
| SCHEMBL18172315 | 0.79 | BRD4 (0.43) | BRD4ERN1BRD2 | |
| SCHEMBL19726804 | 0.78 | ERN1 (0.52) | BRD4ERN1 | |
| SCHEMBL18172308 | 0.77 | GLA (0.41) | GLAAAK1 | |
| SCHEMBL18181083 | 0.72 | CYP1A2 (0.58) | BRD4CREBBPERN1BRD2 | |
| SCHEMBL20832906 | 0.72 | CYP1A2 (0.46) | BRD4ERN1 | |
| SCHEMBL19231421 | 0.72 | ERN1 (0.48) | BRD4CREBBPERN1BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107750251-B | Isoxazolyl-substituted imidazopyridines | 塞尔森瑞科有限责任公司 | 2020-09-01 | — | — | CN | disclosed |
| US-10428065-B2 | Isoxazolyl substituted imidazopyridines | CELLCENTRIC LTD (GB) | 2019-10-01 | — | — | US | disclosed |
| EP-3286188-B1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2019-03-20 | — | — | EP | disclosed |
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2018-04-19 | — | — | US | disclosed |
| EP-3286188-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | Cellcentric Ltd (GB) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016170323-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | EP300, HDAC3, HDAC1 | BRD4 17/4885CREBBP 16/4885ERN1 2258/4885 |
| US-10428065-B2 | Isoxazolyl substituted imidazopyridines | EP300, HDAC3, HDAC1 | BRD4 17/4885CREBBP 16/4885ERN1 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.